Hengrui Takes Focused Approach Amid China Inc's Global Drive
China’s largest innovative domestic drug maker will only take global those products that play into its strengths, chairman Piaoyang Sun declares.
You may also be interested in...
China has emerged as a major new force in global pharma R&D amid a "boom" in activity, with not one but two of its companies entering the top 25 by pipeline size for the first time.
Plus deals involving GC Cell/Rivaara Immune, Sperogenix/Santhera, EOFlow/Zihipp, Grand/ITM, Tasly/Sutro, LegoChem/Iksuda, Nuance/Aerogen, Frontier/AffiRiS and Piramal/Yapan.
While strong growth in China's immuno-oncology sector continued in the last quarter, the momentum appears to be slowing, affecting by multiple factors including intense competition in the sector and price cuts related to reimbursement listing, while regulatory authorities have already warned about what they see as the wasting of resources on "redundant" development activities.